Piper Sandler analyst Edward Tenthoff maintains $RAPT Therapeutics (RAPT.US)$ with a hold rating, and adjusts the target price from $7.97 to $2.
According to TipRanks data, the analyst has a success rate of 32.2% and a total average return of -12.6% over the past year.
Furthermore, according to the comprehensive report, the opinions of $RAPT Therapeutics (RAPT.US)$'s main analysts recently are as follows:
The decision to halt Rapt Therapeutics' zelnecirnon program was influenced by feedback from the FDA, which indicated challenges in conclusively disproving drug-induced liver failure. The discontinuation, paired with the current ambiguity surrounding the development of next-generation compounds and the potential need for additional capital, positions Rapt as a company requiring further evidence before gaining confidence in its outlook.
The FDA's request for definitive evidence concerning liver SAE was more conservative than experts anticipated. This was noted alongside the positive indications of efficacy from the Phase 2b trials, which augur well for the development of next-generation compounds. Anticipation is high for forthcoming data to evaluate the potential.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
